ALSO NOTED: Canada nixes Lilly's Parkinson's drug; Company looks to snap up ex-Pfizer workers;

> Eli Lilly's Permax will be persona non grata in Canada as of August 30. After studies showed the Parkinson's treatment can cause serious heart-valve damage, Lilly in March voluntarily pulled Permax from the U.S. market. Now, Health Canada is ordering the company to stop selling the drug there. Report

> Health Canada also becomes the latest regulator to announce it's reviewing safety data on Prexige, the Novartis Cox-2 inhibitor that Australia withdrew from the market earlier this week. Release

> Laid-off Pfizer staffers may have reason to hope: A pharmaceutical services company is opening an Ann Arbor location, and it's eyeing ex-Pfizer types. Report

> The FDA wants more time to review Endo Pharmaceuticals' supplemental new drug app for the pain med Frova. Endo had applied to expand Frova's label to short-term prevention of menstrual migraine. Report

And Finally... Lyrica isn't making hay only for Pfizer. The $1.2 billion nerve-pain and epilepsy med is bestowing plenty of moolah onto its alma mater, Northwestern University, where chemist Richard Silverman laid the groundwork necessary for its development. Blog

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.